TBPH Earnings

TBPH reported its FY2025Q3 earnings on 2025-11-10, showcasing a revenue of 19.99M against an estimate of 19.90M, resulting in a 0.45% surprise. The EPS was 0.07, surpassing the expected -0.03 by 333.33%. The stock experienced a 22.68% price change on the earnings day and a 15.32% change over the next five days, reflecting market reactions to the results.

Following TBPH's FY2025Q3 earnings announcement on 2025-11-10, the stock price moved by 22.68% on the day of the release. Over the subsequent five days, it saw a 15.32% change. Historically, TBPH's stock price tends to shift by an average of -3.01% in the 10 days leading up to earnings and 0.54% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate TBPH's annual revenue to reach 43.00M, while the EPS is projected at 1.00. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates revised downward by -6.86% over the past three months, indicating analyst expectation in the company's performance.

The correlation between TBPH's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved revised downward by -6.86%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, TBPH's stock price typically moves by -3.01% in the 10 days before its earnings and 0.54% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 1.00 and revenue of 43.00M.

The earnings call highlighted strong financial performance with YUPELRI's sales growth and a robust cash position. The company's strategic focus on the CYPRESS study and potential ampreloxetine launch is promising, despite some regulatory risks. The Q&A revealed confidence in study design and operational execution, with analysts showing interest in future capital returns and pipeline evaluations. Overall, the positive financial metrics, strategic milestones, and optimistic outlook outweigh the risks, suggesting a positive stock price movement.